These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 29520231)

  • 1. Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells.
    Zhu X; Shen X; Qu J; Straubinger RM; Jusko WJ
    Front Pharmacol; 2018; 9():84. PubMed ID: 29520231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways.
    Miao X; Koch G; Shen S; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
    J Pharm Sci; 2024 Jan; 113(1):235-245. PubMed ID: 37918792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated
    Wang X; Niu J; Li J; Shen X; Shen S; Straubinger RM; Qu J
    Mol Cell Proteomics; 2018 Apr; 17(4):655-671. PubMed ID: 29358341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteome characterization of human pancreatic cyst fluid from intraductal papillary mucinous neoplasm by liquid chromatography/tandem mass spectrometry.
    Park J; Han D; Do M; Woo J; Wang JI; Han Y; Kwon W; Kim SW; Jang JY; Kim Y
    Rapid Commun Mass Spectrom; 2017 Oct; 31(20):1761-1772. PubMed ID: 28815810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells.
    Miao X; Koch G; Ait-Oudhia S; Straubinger RM; Jusko WJ
    Front Pharmacol; 2016; 7():421. PubMed ID: 27895579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry.
    Yoshida K; Kuramitsu Y; Murakami K; Ryozawa S; Taba K; Kaino S; Zhang X; Sakaida I; Nakamura K
    Anticancer Res; 2011 Jun; 31(6):2103-8. PubMed ID: 21737628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global Proteomic Profiling of Drosophila Ovary: A High-resolution, Unbiased, Accurate and Multifaceted Analysis.
    Velentzas AD; Anagnostopoulos AK; Velentzas PD; Mpakou VE; Sagioglou NE; Tsioka MM; Katarachia S; Manta AK; Konstantakou EG; Papassideri IS; Tsangaris GT; Stravopodis DJ
    Cancer Genomics Proteomics; 2015; 12(6):369-84. PubMed ID: 26543083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines.
    Mori-Iwamoto S; Kuramitsu Y; Ryozawa S; Taba K; Fujimoto M; Okita K; Nakamura K; Sakaida I
    Mol Med Rep; 2008; 1(3):429-34. PubMed ID: 21479428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma.
    Shao F; Huang M; Meng F; Huang Q
    Front Pharmacol; 2018; 9():584. PubMed ID: 29922161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anacardic acid inhibits pancreatic cancer cell growth, and potentiates chemotherapeutic effect by Chmp1A - ATM - p53 signaling pathway.
    Park M; Upton D; Blackmon M; Dixon V; Craver S; Neal D; Perkins D
    BMC Complement Altern Med; 2018 Feb; 18(1):71. PubMed ID: 29463243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocorydine decrease gemcitabine-resistance by inhibiting epithelial-mesenchymal transition via STAT3 in pancreatic cancer cells.
    Zhang QB; Ye RF; Ye LY; Zhang QY; Dai NG
    Am J Transl Res; 2020; 12(7):3702-3714. PubMed ID: 32774728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine.
    Yu Y; Ding F; Gao M; Jia YF; Ren L
    Oncol Lett; 2019 Sep; 18(3):3065-3071. PubMed ID: 31452783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ITRAQ-Based Proteomics Analysis of Triptolide On Human A549 Lung Adenocarcinoma Cells.
    Li F; Zhao D; Yang S; Wang J; Liu Q; Jin X; Wang W
    Cell Physiol Biochem; 2018; 45(3):917-934. PubMed ID: 29428961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling.
    Wang B; Shen C; Li Y; Zhang T; Huang H; Ren J; Hu Z; Xu J; Xu B
    Onco Targets Ther; 2019; 12():5751-5765. PubMed ID: 31410021
    [No Abstract]   [Full Text] [Related]  

  • 15. Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.
    Gu WJ; Liu HL
    Anticancer Drugs; 2013 Jul; 24(6):566-76. PubMed ID: 23525071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways.
    Brandi J; Dando I; Pozza ED; Biondani G; Jenkins R; Elliott V; Park K; Fanelli G; Zolla L; Costello E; Scarpa A; Cecconi D; Palmieri M
    J Proteomics; 2017 Jan; 150():310-322. PubMed ID: 27746256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of herbal medicines and natural products: an alternative approach to overcoming the apoptotic resistance of pancreatic cancer.
    Li L; Leung PS
    Int J Biochem Cell Biol; 2014 Aug; 53():224-36. PubMed ID: 24875648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells.
    Zhu X; Shen X; Qu J; Straubinger RM; Jusko WJ
    CPT Pharmacometrics Syst Pharmacol; 2018 Sep; 7(9):549-561. PubMed ID: 30084546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative proteomics and n-glycoproteomics reveal the synergistic anti-tumor effects of aspirin- and gemcitabine-based chemotherapy on pancreatic cancer cells.
    Li X; Kong R; Hou W; Cao J; Zhang L; Qian X; Zhao L; Ying W
    Cell Oncol (Dordr); 2024 Feb; 47(1):141-156. PubMed ID: 37639207
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.